Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0CDMSL |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | SCAPDL1xSCACD47 |
|||||
| Synonyms |
SCAPDL1xSCACD47
Click to Show/Hide
|
|||||
| Antibody Type | Bispecific antibody (BsAb) |
|||||
| Antigen Name | Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
CN117337196A Compound91 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ -20% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ -5% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 2% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 5% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 18% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 25% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 42% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 50% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 55% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 70% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
CN117337196A Compound93 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ -10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ -5% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ -5% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line Calu6 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 0% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 5% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line U87.MG cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 7% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 8% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line T47D cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | T47D cells | CVCL_0553 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 15% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 15% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line U87.MG cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 18% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line T47D cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | T47D cells | CVCL_0553 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 18% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line Calu6 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 20% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 25% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 28% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line T47D cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | T47D cells | CVCL_0553 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 30% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 35% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line U87.MG cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
| Experiment 18 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 38% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line T47D cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | T47D cells | CVCL_0553 | ||
| Experiment 19 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 38% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line Calu6 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||
| Experiment 20 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 45% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 21 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 60% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 22 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 75% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line U87.MG cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
CN117337196A Compound92 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ -5% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 5% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 16% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 17% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.xPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 20% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 25% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 38% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 38% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 40% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 55% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 65% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 80% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
CN117337196A Compound87 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 15% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 15% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung squamous cell carcinoma | NCI-H520 cells | CVCL_1566 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 20% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung squamous cell carcinoma | NCI-H520 cells | CVCL_1566 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 30% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 40% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 42% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung squamous cell carcinoma | NCI-H520 cells | CVCL_1566 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 50% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
CN117337196A Compound90 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 20% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 90 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 45% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 90 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 65% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 90 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
CN117337196A Compound89 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 20% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 22% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung squamous cell carcinoma | NCI-H520 cells | CVCL_1566 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 25% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 35% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 40% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 42% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung squamous cell carcinoma | NCI-H520 cells | CVCL_1566 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 65% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung squamous cell carcinoma | NCI-H520 cells | CVCL_1566 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 70% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 75% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||